Leo Pharma agreed to license a Tanabe Pharma oral therapy for a pair of genetic light-sensitive skin diseases, with payments totaling up to $435 million in upfront and near-term milestones. The deal strengthens Leo’s rare-disease pipeline while the asset awaits a regulatory decision by the FDA. The licensing structure is designed to give Leo access to an oral option in dermatology’s monogenic segment, where commercial differentiation often hinges on safety, administration route, and label scope. For Tanabe, the partnership provides a pathway for monetization beyond Japan while retaining development continuity aligned to regulatory progress. For industry watchers, the transaction is another example of late-stage platform consolidation in dermatology and rare disease, where Big Pharma-style economics are increasingly mirrored by mid-cap specialists through licensing deals with sizable milestone packages.